Phase II Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection, NEOSTAR/INDUCTION - Strategic Alliance: BMS
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NEOSTAR
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 12 Jun 2017 Planned End Date changed from 1 Jul 2021 to 1 Jun 2021.